Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

← catalyst calendar

NCT05203172 · readout in 1,077 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
46estimated
Sites
67
Countries
Australia, Brazil, Canada +14

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-07-05actualWhen the study began enrolling
Primary completion2029-07-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2029-07-31estimatedThe whole study's end, after follow-up
First posted2022-01-24actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-04-07actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Solid Tumors

Interventions

  • Drug: Binimetinib only treatment
  • Drug: Encorafenib only Treatment
  • Drug: Encorafenib & Binimetinib Treatment
  • Drug: Treatment of Encorafenib & Binimetinib & Ribociclib
  • Drug: Treatment of Encorafenib & Binimetinib & Cetuximab

Primary outcomes

what the primary-completion date above is the date OF
Number of participants with adverse events leading to permanent discontinuation of study intervention
measured Baseline up to approximately 5 years
Number serious adverse events reported for all participants
measured Baseline up to approximately 5 years

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed